In a major positive step for global respiratory health, Member States at the 78th World Health Assembly (WHA), held May 19–27 ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.

Research shows RSV leads to high hospitalization rates in adults, emphasizing the importance of enhanced surveillance and ...

Cigarette smoking is the leading cause of preventable death worldwide. It causes chronic lung disease and predisposes individuals to acute lung injury and pulmonary infection. Alveolar macrophages are ...

Merck's Enflonsia vaccine for respiratory syncytial virus won approval from the Centers for Disease Control and Prevention's ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

By a 5-2 vote, the Advisory Committee on Immunization Practices endorsed Merck’s Enflonsia for babies born during or entering their first RSV season.

In a move that has left many public health observers reeling, a newly appointed vaccine committee under Health and Human Services Secretary Robert F. Kennedy Jr. has voted to recommend an RSV shot for ...

Whatever the cause, it's important to find lung cancer early when it's curable. That's why the Lung Force walk comes together every year to raise awareness. "It is very important.

Next up, there were some updates from the FDA about a new RSV vaccine for infants and a new treatment for gonorrhea. Andrea, tell us more about both of those. Garcia: So last week, the FDA approved a ...

Respiratory syncytial virus (RSV) is a leading cause of hospitalization in infants and young children, placing a significant burden on families, hospitals, and the healthcare system. Recent ...